

## WHAT IS KETAMINE?

Ketamine is a strong analgesic medication that primarily works as a N-Methyl-D-aspartate (NMDA) receptor antagonist. There are also additional possible mechanisms of action, including, central anti-inflammatory effects.

Ketamine infusions have been known as a successful treatment option for patients diagnosed with central neuropathic pain syndrome, complex regional pain syndrome, and diabetic neuropathy after the failure of other medications and interventions.



At Allevio Pain Management, we administer intravenous ketamine safely and based on up-to-date recommendations and guidelines. Patients receive intravenous ketamine over three hours under the constant supervision of specialists and the continuous monitoring of vital signs to minimize the risk of acute, dose-dependent, and adverse effects of ketamine. These effects include altered states of consciousness, dizziness, visual changes, altered hearing, hypertension, nausea, and vomiting.

## WHAT IS A KETAMINE INFUSION?

It is an infusion that uses a unique and clinically proven combination of ketamine and lidocaine to help patients improve their pain and mood. It has been shown to help patients either reduce or eliminate the use of opioids for pain. To avoid any potential side effects, we administer ketamine safely in three hours.

## WHAT ARE THE INFUSIONS FOR?


- Neuropathic Pain
- Diabetic Neuropathy
- Depression
- Anxiety
- Post-traumatic Stress Disorder (PTSD)
- Complex Regional Pain Syndrome

For more information about clinic policies, patient satisfaction, and the treatment's impact on quality of life, please [contact us](#) through our website. Questions may also be sent to [info@allevioclinic.com](mailto:info@allevioclinic.com).

## 1 IN 4 CANADIANS SUFFER FROM CHRONIC PAIN

According to Health Canada, an estimated 7.63 million Canadians suffer from chronic pain.

(Source: Health Canada: Canadian Pain Task Force Report: Oct 2020. <https://www.canada.ca/en/health-canada/corporate/about-health-canada/public-engagement/external-advisory-bodies/canadian-pain-task-force/report-2020.html>)



**Drug Cost Per Opioid Patient**  
(Per Patient Annually)

## ECONOMIC IMPACT

One study in the 2020 Canadian Pain Task Force Report cited \$21,360 as the direct and indirect annual health care cost per opioid pain patient.

(Source: FAIR Health Study: The Impact of the opioid crisis on the healthcaresystem, Sept 2016. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278808>)


## KETAMINE-LIDOCAINE INFUSION COST

A single long infusion treatment for a chronic pain patient is \$1,700 and the treatment protocol for a year costs a total of \$10,200, compared to an average \$21,360 in care and a further \$17,554 in employer costs and impact.

## KETAMINE-LIDOCAINE INFUSIONS REDUCE PAIN BETTER AND FOR LONGER THAN OPIATES



Over a 36 week study, our Ketamine-Lidocaine infusion patients had a significant reduction in symptoms of chronic pain.

From 2013 - 2019, of the 838 Allevio patients who were prescribed narcotics, **all 838 patients had decreased narcotic consumption, 559 of those patients completely eliminated narcotic use.**



## BETTER QUALITY OF LIFE

Over the 36 week study, our Ketamine-Lidocaine infusion patients experienced significant reductions in symptoms of pain. They also experienced significant improvement in severity and symptoms of depression, general mood and overall enjoyment of life.



## HIGHER PATIENT SATISFACTION, LESS PAIN, LOWER COST... BETTER PATIENT OUTCOMES

Patients in our ketamine-lidocaine infusion program have consistently rated Allevio with high levels of satisfaction. They experience substantial improvements in not only their pain but also their symptoms of depression, mood, and overall wellbeing.

